Sana Biotechnology to Present at December 2024 Investor Conferences

Rhea-AI Summary

Sana Biotechnology (NASDAQ: SANA) has announced its participation in two major investor conferences this December. The company's President and CEO, Steve Harr, will deliver business overviews and updates at both events. The first presentation will be a panel participation at Citi's 2024 Global Healthcare Conference on December 3 at 2:30 p.m. ET, followed by a presentation at the 7th Annual Evercore ISI HealthCONx Conference on December 4 at 2:35 p.m. ET. Both presentations will be available via webcast on Sana's website, with replays accessible for 30 days after the events.

News Market Reaction

-1.21%

1 alert

-1.21% News Effect

On the day this news was published, SANA declined 1.21%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SEATTLE, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in December. The presentations will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer.

• Sana will participate on a panel at Citi’s 2024 Global Healthcare Conference at 2:30 p.m. ET on Tuesday, December 3, 2024.
• Sana will present at the 7^th Annual Evercore ISI HealthCONx Conference at 2:35 p.m. ET on Wednesday, December 4, 2024.

The webcasts will be accessible on the Investor Relations page of Sana’s website at https://sana.com/. A replay of each presentation will be available at the same location for 30 days following the conference.

About Sana Biotechnology
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, WA, Cambridge, MA, South San Francisco, CA, Bothell, WA and Rochester, NY. For more information about Sana Biotechnology, please visit https://sana.com/.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the Company’s vision; the Company’s participation at Citi’s 2024 Global Healthcare Conference and the 7^th Annual Evercore ISI HealthCONx Conference; and the subject matter of the Company’s presentations at these conferences. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company’s strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company’s current and future research and development programs, preclinical and clinical trials, as well as economic, market and social disruptions. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s SEC reports, including but not limited to its Annual Report on Form 10-Q dated November 8, 2024. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.

Investor Relations & Media:
Nicole Keith
investor.relations@sana.com
media@sana.com

FAQ

When will Sana Biotechnology (SANA) present at Citi's Global Healthcare Conference in December 2024?

Sana Biotechnology will participate in a panel at Citi's Global Healthcare Conference on Tuesday, December 3, 2024, at 2:30 p.m. ET.

What time is Sana Biotechnology's (SANA) presentation at the Evercore ISI HealthCONx Conference?

Sana Biotechnology will present at the 7th Annual Evercore ISI HealthCONx Conference on Wednesday, December 4, 2024, at 2:35 p.m. ET.

How long will Sana Biotechnology's (SANA) December 2024 investor conference webcasts be available for replay?

The webcasts will be available for replay on Sana's website for 30 days following each conference.

Where can investors watch Sana Biotechnology's (SANA) December 2024 conference presentations?

Investors can access the webcasts through the Investor Relations page of Sana's website at https://sana.com/.